COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE
|
|
- Meagan Bishop
- 6 years ago
- Views:
Transcription
1 The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE ADOPTION FOR CONSULTATION BY CVMP 11 NOVEMBER 1998 COMMENTS REQUESTED BEFORE 1 JUNE 1999 DISCUSSION IN IWP FEBRUARY 2000 ADOPTION BY CVMP MARCH 2000 DATE FOR COMING INTO EFFECT 1 JANUARY This note for guidance will be developed as needed and as understanding of the issues evolves. Public 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Switchboard: ( ) Fax: ( ) E_Mail: mail@emea.eudra.org EMEA 2000 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged
2 INTRODUCTION The use of plasmid DNA as a form of vaccination has progressed very rapidly in the last few years and several trials of this type of vaccination are in progress. DNA vaccination involves the inoculation of a gene(s) encoding a relevant antigen against which an immune response is desired, under the control of a promoter, which will permit its expression in the vaccinated animal. This gene construct is contained, for manipulation and for manufacturing purposes, within a bacterial plasmid DNA molecule. This type of vaccine has potentially important advantages over the direct inoculation of the antigen itself, e.g., it may provide a much wider stimulation of the immune system, including the stimulation of a cytotoxic T cell response. It can also have advantages over the use of a live attenuated micro-organism, e.g., the avoidance of breakthrough of disease arising from inadequately attenuated infectious agents. Furthermore, the manufacture of a plasmid DNA vaccine is likely to be simpler than for more traditional forms of vaccine and DNA vaccines are likely to have greater stability. SCOPE OF THE DOCUMENT This document is intended to provide advice to manufacturers seeking marketing authorisation for a nucleic acid vaccine for use in animals when the vaccine consists of a bacterial DNA plasmid. This document is applicable to vaccines consisting of plasmid DNA, non-amplifiable in eukaryotic cells. New developments involving plasmid DNA delivered by live vectors (e.g. bacteria) or capable of amplification in the vaccinated animal by any mechanisms, are not within the scope of this document. As most of the DNA vaccines will be composed of a mixture of plasmids coding for different immunogens isolated from a single pathogen (virus, bacteria or parasites) or from different pathogens (mono- and multivalent DNA vaccines), DNA vaccine, as defined in the document, should be understood as a range of vaccine plasmids destined for use in a given species to induce an immune response. The guideline should be read in conjunction with European Directives and other specialised guidelines, since all the appropriate standard requirements for veterinary vaccines are applicable, also, to the products within the scope of this document. The production of other biological products can provide the necessary experience on which a plasmid DNA biological product should be controlled. Therefore, these guidelines will focus on particular aspects relevant to this novel form of vaccination, developmental testing and control of DNA vaccines keeping in mind that each vaccine should be considered on a case-by-case basis. It is intended as guidance to help manufacturers to define assays to be carried out and to build up the application dossier. CVMP/IWP/07/98-FINAL EMEA /7
3 SPECIAL ISSUES There are several aspects of the use of a DNA vaccine, which have to be considered at the preclinical safety stage: 1. The plasmid DNA which is internalised by the cells of the vaccinated animal may integrate into the chromosomes of the vaccinated animal and disrupt the normal replicative state of that cell, causing uncontrolled cell division and tumourigenesis: After injection of DNA into an animal, a small proportion of the DNA molecules enters cells. The probability of any DNA molecule integrating into the chromosome is also low and given that oncogenesis is a multi-factorial event, the risk of insertional mutagenesis is exceedingly low. So far the integration of plasmid DNA into chromosomal DNA of a vaccinated animal has not been observed. However, probability of integration events occurring may differ according to the tissue type, the route of application, the amount of plasmid administered and the age of the vaccinated animal. 2. The method of vaccination may result in undesirable immune reactions: The mechanism of the immune response to an antigen, which is expressed due to injected DNA, is poorly understood. This raises concerns about possible adverse effects on the immune system, including auto-immune reactions. Although DNA can have a very low immunogenic potential, bacterial DNA can have a mitogenic or immunostimulatory effect. This property may be used to advantage in some DNA vaccines and is under active investigation. As with the co-use of cytokines, the specific incorporation of immunostimulatory sequences in any form should proceed with care. 3. The additional use of genes encoding cytokines or co-stimulatory molecules may pose additional risks: There is considerable interest in the co-administration of a gene encoding a cytokine in order to direct a specific type of immune response. However, this could have detrimental effects especially if the cytokine has been introduced on an expression plasmid whose expression cannot be terminated. Furthermore, it will be important to avoid the induction of immunity towards an encoded cytokine, which could have untoward and undesirable consequences for a vaccine recipient. 4. The expressed antigen may itself have undesirable biological activity: An encoded antigen may exhibit undesirable biological activity and if this is the case appropriate steps may have to be taken (e.g. deletion mutagenesis) to eliminate the activity while retaining the desired immune response. POINTS TO BE ADDRESSED FOR A DNA VACCINE CVMP/IWP/07/98-FINAL EMEA /7
4 As indicated above, the standard data requirements for veterinary vaccines have to be addressed in the application dossier. The information must be presented in accordance with the format set out in the Notice to Applicants. The following are given as examples of the level of detail and points to be addressed, as appropriate, in the various sections of the dossier. A) ANALYTICAL SECTION: A detailed description on the development of the vaccine plasmid should be provided. This should include details of the gene encoding the protein, against which an immune response is sought, information on the construction of the entire plasmid and the host bacterial cell. The origin of the gene of interest should be described in detail, such as the name of the microorganism or cell from which the gene was derived, the origin of the source, its species, passage history, subtype and isolation strategy followed. The rationale for the use of the gene(s) should be discussed and the sequence of the wild-type gene and the antigenic properties of the encoded protein in its natural state should be provided. The steps in the construction of the entire vaccine plasmid should be described, including the source of the plasmid(s) used and subclones generated during the cloning procedure. Functional components such as regulatory sequences (origins of replication, viral/eukaryotic promoters, introns, termination sequences) and selection markers should be clearly indicated and information on the source and function of these elements should be provided when appropriate. Sequence data on the entire plasmid will be required and the use of all specific elements or regions of DNA should be justified. DNA sequence homology checks of the plasmid with all published DNA sequence data of the target species should be performed and the information given in the application dossier. An informative restriction map of the vaccine plasmid should be presented. Special attention should be given to the nature of a selection marker. The use of certain selection markers such as resistance to therapeutic antibiotics as well as certain sequences such as retroviral-like long terminal repeats (LTRs) and oncogenes should be avoided as far as possible; if not, a justification should be given in the dossier. The rationale for the choice of the host bacterial cell used for production of plasmid should be provided along with a description of its source, phenotype and genotype. It should be demonstrated that the host cell is free from bacteriophage and other adventitious agent contamination. The identity of the vaccine plasmid after transfection into the bacterial cell to be used for production and the phenotype of the transfected cell should be confirmed. Since rearrangements of the plasmid are unacceptable, data on the stability of the plasmid within the bacterial cell will be required. The expression of prokaryotic genes, such as a selection marker, in a eukaryotic cell line should be investigated. Cell seed The production of plasmid DNA vaccines should be based on a well defined master cell seed (MCS) and working cell seed (WCS) system. The cloning and culturing procedures used for the establishment of the MCS should be described. The origin, form, storage, use, and expected duration at the anticipated rate of use must be described in full for all cell seeds. The MCS should be fully characterised and specific phenotypic features which form a basis for identification should be described. The sequence of the entire plasmid should be established at the stage of the MCS. WCSs should be adequately characterised and meet established acceptance criteria. The viability of the host-vector system in the MCS and WCS under storage and recovery conditions should be CVMP/IWP/07/98-FINAL EMEA /7
5 determined. It should be demonstrated that MCS and WCS are free from extraneous microbial agents. Production, validation and in process testing Procedures and materials used during production fermentation and harvesting should be described in detail. Data on consistency of fermentation and harvesting conditions, culture growth and plasmid yield should be presented. Relevant in-process controls should be identified and rejection criteria during fermentation and harvesting should be established. The minimum and maximum level of cell growth to be accepted during production should be defined and should be based on information concerning the stability of the host cell/plasmid system up to the maximum level of fermentation used in production. At the end of fermentation and harvesting, bacterial cell/plasmid characteristics should be investigated. This may include restriction fragment analysis, and the yield of both cells and plasmid. Any methods used to extract the plasmid DNA and remove and/or reduce the concentration of unwanted materials must be described in detail and the process explained and validated. Clearance capacity for removal of contaminants will be established for the purification process by the difference in contaminant levels before and after each purification step. Batch acceptance will be established on the basis of compliance with the upper acceptance limits defined for each contaminant. Special attention should be given to the removal of endotoxin. Validated in-process controls for any potential contaminants of concern should be developed and routine batch test upper acceptance limits established, based on data from tests showing the safety of that concentration. Routine control of bulk vaccine and finished product Identity The molecular form of each batch of plasmid should be assessed using a suitable technique, e.g. agarose gel electrophoresis, and an informative restriction analysis(es) should be performed. Characterisation of in-vitro expression of the correct antigen should be documented through the use of specific assays, such as Western Blot, IFA or ELISA. For vaccines, which include plasmids encoding non-antigenic biologically active molecules, these plasmids should also be expressed in vitro and expression assessed with an appropriate bioassay. Other tests as appropriate and depending on the method of purification and production and the nature of the plasmid should also be applied. DNA content A quantitative test for total DNA content per ml or per dose should be carried out on each batch of finished product. Tests for contaminants The purity of each batch of plasmid vaccine must be assessed and the level of contaminants shall be within specified limits to be set for any identified contaminant of bacterial-cell origin. Each CVMP/IWP/07/98-FINAL EMEA /7
6 batch of product must also be tested for endotoxin, unless it is demonstrated that the bacterial host is endotoxin negative and that there is no endotoxin identified in three successive batches, and shown to be within the limit established as safe for the product. Additional tests may be required depending on the production process used, the results obtained from purification, validation and safety studies. Batch potency test An appropriate assay for the potency of the plasmid vaccine will be required. The most appropriate approach will vary depending on the composition of the vaccine, the nature of the disease, the expressed antigen(s) and the immune response being sought. Thus, the design of a potency assay will require careful consideration by the manufacturer and will be assessed on a case-by-case basis. Whatever the assay, an approved in-house reference preparation will be required and should be established from appropriately characterised batch of vaccine. Quantification of expression of the correct antigen in vitro should be performed, using qualitative and quantitative test methods (e.g. ELISA). Fully validated in vitro expression assays can be considered sufficient for establishing batch potency and are preferred, wherever possible, to assays using animals, provided that correlation has been shown for the reference preparation between antigen expression in-vitro and potency invivo. Batch safety test The routine batch safety tests should be conducted with ten doses of product administered to the target species B) SAFETY TESTING Safety testing should be carried out in accordance with requirements of Part 7 of the Annex to Council Directive 81/852/EEC as amended. The following are examples of specific points, which should be addressed as appropriate under the headings indicated. Batches with maximal DNA content and potency should be used. The overdose studies should be conducted with 10 doses of the finished product unless justification can be provided for the use of a fewer number. Distribution studies Distribution studies data will be derived for the DNA vaccines (as defined in 1). Distribution data obtained with one type of plasmid should also be applicable to all other plasmids sharing the same backbone and differing only by the cloned antigenic gene provided that the inserts are approximately the same size. The route of DNA inoculation as well as the amount of DNA administered may influence the distribution of the DNA in the body. Localisation studies should be designed to determine the distribution of the DNA after administration via the proposed route and employing the proposed method of inoculation. Using the most sensitive methods available, the extent of DNA distribution to and the cellular uptake by the target and the surrounding tissues including the draining lymph nodes should be analysed at various time points (e.g. day 1, day 7 and one month after vaccination or at a longer time, when appropriate). The timing of sampling should take into CVMP/IWP/07/98-FINAL EMEA /7
7 account information on the duration of gene expression and the persistence of the DNA in the body of the vaccinated animal. Integration and tumourigenesis These studies, if necessary, should be undertaken with the DNA vaccine (as defined in 1) and not with each individual plasmid, when combined. A step by step analysis should be carried out. As a first step, checks should be undertaken for the presence of plasmid DNA in the target tissue and draining lymph node. If, or when, plasmid DNA is detected, the most sensitive methods available should be used to investigate their integration. If integration is detected or suspected, carry out a test for tumourigenicity in a susceptible laboratory animal system. The incidence of tumors in the target species, particularly at the site of injection and in the target tissue, should be recorded at the end of each experiment in the safety and efficacy studies. Post marketing, any reports of tumours in the target species should be carefully monitored, as part of pharmacovigilance. Reproductive toxicity Standard studies on impact on reproductive performance will be conducted for DNA vaccines as for other types of vaccine. The possibility of migration of the DNA to gonadal tissues and potential DNA transfer into germ line cells of vaccinated male and female animals should be considered. If necessary, the distribution studies, mentioned above, should be extended to provide information on this point. Examination of immunological functions Specific studies should be conducted to address the possibility of adverse effects on the immune system, particularly if cytokine genes are used as adjuvants. C) EFFICACY STUDIES Efficacy field studies should be carried out according to Part 8 of the annex to Council Directive 81/852/EEC as amended. The standard requirements for efficacy testing of veterinary vaccines are applicable to these products. Tests should be conducted with batches with minimum DNA content and potency. For these DNA vaccines, information will be required on the duration of the immune response (e.g. stability of antibody levels) and on the correlation between the immunological parameters measured in-vivo and protection. The data generated can be used to support the recommended vaccination schedule. CVMP/IWP/07/98-FINAL EMEA /7
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
The European Agency for the Evaluation of Medicinal Products EMEA/CVMP/550/02-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) GUIDELINE ON REQUIREMENTS FOR CONCURRENT ADMINISTRATION OF IMMUNOLOGICAL
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 17 March 2008 Doc. Ref. EMEA/CVMP/IWP/105504/2007-CONSULTATION COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE
More informationLondon, 11 October 2006 Doc. Ref. EMEA/CHMP/BWP/271475/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency 1 2 London, 11 October 2006 Doc. Ref. 3 4 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) 5 DRAFT 6 7 GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY MEDICINAL
More informationCOMMISSION DIRECTIVE 2009/120/EC
15.9.2009 Official Journal of the European Union L 242/3 DIRECTIVES COMMISSION DIRECTIVE 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on
More informationGuideline on requirements for the production and control of immunological veterinary medicinal products
14 June 2012 EMA/CVMP/IWP/206555/2010 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on requirements for the production and control of immunological veterinary Draft agreed by Immunologicals
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationReflection paper on the use of heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products
10 September 2015 EMA/CVMP/IWP/37924/2014 Committee for Medicinal Products for Veterinary Use (CVMP) Reflection paper on the use of heat treatment to inactivate endogenous retroviruses in live immunological
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationPRODUCTION AND QUALITY CONTROL OF CYTOKINE PRODUCTS DERIVED BY BIOTECHNOLOGICAL PROCESSES
PRODUCTION AND QUALITY CONTROL OF CYTOKINE PRODUCTS DERIVED BY BIOTECHNOLOGICAL PROCESSES Guideline Title Production and Quality Control of Cytokine Products derived by Biotechnological Processes Legislative
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More information5.14. GENE TRANSFER MEDICINAL PRODUCTS FOR HUMAN USE. Recombinant vectors Gene transfer medicinal products for human use
EUROPEAN PHARMACOPOEIA 6.0 5.14. Gene transfer medicinal products for human use 01/2008:51400 corrected 6.0 5.14. GENE TRANSFER MEDICINAL PRODUCTS FOR HUMAN USE This general chapter is published for information.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/32775/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL
More informationNew proposal from the EC:
New proposal from the EC: Gene therapy medicinal product means a biological medicinal product which has the following characteristics: a. it contains an active substance which contains or consists of a
More informationGUIDELINES FOR GENERATING PRE-CLINICAL AND CLINICAL DATA FOR r-dna BASED VACCINES, DIAGNOSTICS AND OTHER BIOLOGICALS, 1999
Biotechnology is poised for economic and social progress in the developed and developing countries. The biotechnology research, development and applications are growing at a rapid rate. This would lead
More informationMAIN OUTCOMES OF DISCUSSION FROM WHO CONSULTATION ON NUCLEIC ACID VACCINES. I. Knezevic, R. Sheets Feb, 2018 Geneva, Switzerland
MAIN OUTCOMES OF DISCUSSION FROM WHO CONSULTATION ON NUCLEIC ACID VACCINES I. Knezevic, R. Sheets 21-23 Feb, 2018 Geneva, Switzerland CONTEXT OF DISCUSSION WHO Consultation held to determine whether the
More informationQuality Control Assays
QUALITY CONTROL An integral part of the Penn Vector Core is its robust quality control program which is carried out by a separate quality control group. Quality control assays have been developed and optimized
More informationAnja Holm Danish Medicines Agency. Genetic vaccines Oslo, 2008
Anja Holm Danish Medicines Agency Genetic vaccines Oslo, 2008 Ministry of Food, Agriculture and Fisheries Danish Veterinary Institute Technical review & discussion of safety issues Author: Anja Holm. Anja
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON
European Medicines Agency Veterinary Medicines and Inspections London, 9 November 2005 Doc. Ref. COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON REQUIREMENTS AND CONTROLS
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) <DRAFT>
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 November 2005 Doc. Ref. EMEA/273974/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) NOTE
More informationGuidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
Annex 2 Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines Introduction 61 Background 62 Scope 62 General considerations 63 Terminology 65 Part A. Manufacturing and quality
More informationICH Topic S 6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Step 5
European Medicines Agency March 1998 CPMP/ICH/302/95 ICH Topic S 6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON PRECLINICAL SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED
More informationCOMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 April 2007 Doc. Ref. EMEA/CHMP/GTWP/367513/2006 COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) CONCEPT PAPER ON The development of a Guideline on clinical
More informationNaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER
Nanoplasmid TM Platform NaNoplasmid TM The Nanoplasmid is a dramatically improved Key Cassette (
More informationWhat are ATMP s: Why do they Require Special Scientific and Regulatory Attention? Christopher A Bravery.
What are ATMP s: Why do they Require Special Scientific and Regulatory Attention? Christopher A Bravery cbravery@advbiols.com CONTENTS What are ATMP s Definitions What makes ATMP s different? Starting
More informationCurrent Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)
Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs) Wei Wei Ph.D Center for Drug Evaluation, National Medical Products Administration (CDE,NMPA) 2018/12/04 Tokyo
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 31 May 2001 CPMP/BWP/41450/98 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON ALLERGEN PRODUCTS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 13 March 1996 CPMP/BWP/243/96 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE
More informationAnnex 4. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology
Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology Replacement of Annex 3 of WHO Technical Report Series, No. 814 Introduction 177
More informationICH Topic Q 3 B Impurities in New Medicinal Products
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit ICH Topic Q 3 B Impurities in New Medicinal Products Step 4, Consensus Guideline, 6 November 1996 TE FOR GUIDANCE
More informationReview of requirements for immunological medicinal products and their evolution since the start of Community legislation on medicines
www.pei.de Review of requirements for immunological medicinal products and their evolution since the start of Community legislation on medicines Dr. Carmen Jungbäck Paul-Ehrlich Institut, Germany London,
More informationBiotechnology DNA technology
Biotechnology Biotechnology is the manipulation of organisms or their components to make useful products The applications of DNA technology affect everything from agriculture, to criminal law, to medical
More informationWhat goes into my Biological Inventory?
What goes into my Biological Inventory? What Information is Required for an Effective Risk Assessment? According to the Laboratory Biosafety Guidelines (2004), the risk group of an organism is determined
More informationGMO Technology Conference
GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October
More informationGuideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells
1 2 3 20 May 2010 EMA/CHMP/GTWP/671639/2008 Committee for the Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically
More informationDoc. Ref. EMEA/CHMP/VWP/141697/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency 1 London, 0 April 00 Doc. Ref. EMEA/CHMP/VWP//00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON QUALITY, NON-CLINICAL AND CLINICAL ASPECTS OF LIVE RECOMBINANT
More informationEuropean Medicines Agency Inspections
European Medicines Agency Inspections London, 3 March 2005 Doc. Ref. EMEA/INS/GMP/82801/2005 COMMUNITY BASIC FORMAT FOR MANUFACTURERS/ IMPORTERS AUTHORISATION 1. Authorisation number 2. Name of authorisation
More informationExpectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products
Expectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products Approved by the IPRP Management Committee on 3 June 2018 12 April 2018 Table of Contents 1. Position Statement... 3 2. Executive
More informationBiotechnology. Chapter 20. Biology Eighth Edition Neil Campbell and Jane Reece. PowerPoint Lecture Presentations for
Chapter 20 Biotechnology PowerPoint Lecture Presentations for Biology Eighth Edition Neil Campbell and Jane Reece Lectures by Chris Romero, updated by Erin Barley with contributions from Joan Sharp Copyright
More informationDevelopment of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach
3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/94528/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE
More informationVICH Topic GL10. Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN NEW VETERINARY DRUG SUBSTANCES
European Medicines Agency Veterinary Medicines and Inspections London, 19 February 2007 Doc. Ref.EMEA/CVMP/VICH/837/99-Rev.1 VICH Topic GL10 Step 7 (after revision at step 9) GUIDELINE ON IMPURITIES IN
More informationOverview: The DNA Toolbox
Overview: The DNA Toolbox Sequencing of the genomes of more than 7,000 species was under way in 2010 DNA sequencing has depended on advances in technology, starting with making recombinant DNA In recombinant
More informationVICH Topic GL44. at Step 4 GUIDELINE ON TARGET ANIMAL SAFETY FOR VETERINARY LIVE AND INACTIVATED VACCINES
European Medicines Agency Veterinary Medicines and Inspections London, 18 September 2007 Doc. Ref. EMEA/CVMP/VICH/359665/2005-CONSULTATION VICH Topic GL44 at Step 4 GUIDELINE ON TARGET ANIMAL SAFETY FOR
More information2014 Pearson Education, Inc. CH 8: Recombinant DNA Technology
CH 8: Recombinant DNA Technology Biotechnology the use of microorganisms to make practical products Recombinant DNA = DNA from 2 different sources What is Recombinant DNA Technology? modifying genomes
More informationSUBMISSION OF COMMENTS ON GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS - EMEA/CHMP/BWP/398498/2005
20 December 2006 European Medicines Agency (EMEA) 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom SUBMISSION OF COMMENTS ON GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL
More informationConsiderations on regulatory aspects
Considerations on regulatory aspects Regulatory framework for medicinal products in the context of therapeutic use of bacteriophages EMA Workshop on 8 June Presented by Zigmars Sebris on 8 June 2015 Regulatory
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationCH 8: Recombinant DNA Technology
CH 8: Recombinant DNA Technology Biotechnology the use of microorganisms to make practical products Recombinant DNA = DNA from 2 different sources What is Recombinant DNA Technology? modifying genomes
More informationICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
More informationVICH Topic GL40. at Step 7 GUIDELINE ON TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW BIOTECHNOLOGICAL/BIOLOGICAL VETERINARY MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 15 November 2005 Doc. Ref. EMEA/CVMP/VICH/811/04- corrigendum 1 VICH Topic GL40 at Step 7 GUIDELINE ON TEST PROCEDURES AND ACCEPTANCE
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE- GENERAL Health systems and products Medicinal products quality, safety and efficacy 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal
More informationConsiderations in Product Development with Advanced Therapies and Cancer Vaccines
Considerations in Product Development with Advanced Therapies and Cancer Vaccines Thomas Hinz Head of Section Therapeutic Vaccines Paul-Ehrlich-Institut hinth@pei.de Thomas Hinz, October 29, 2008, San
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationStandards for Safety Assessments of Food Additives produced Using Genetically Modified Microorganisms
Standards for Safety Assessments of Food Additives produced Using Genetically Modified Microorganisms (Food Safety Commission Decision of March 25, 2004) Chapter 1 General Provisions No. 1 Background on
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More information[DOCKET NO. 96N-0400] Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications
[DOCKET NO. 96N-0400] Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Disease Indications For further information about this document, contact: Valerie A. Butler Center for Biologics
More informationDRAFT GUIDELINE ON SIMILAR MEDICINAL PRODUCTS CONTAINING RECOMBINANT INTERFERON ALPHA
European Medicines Agency London, 18 October 2007 Doc. Ref. EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON SIMILAR MEDICINAL PRODUCTS CONTAINING RECOMBINANT
More informationRegulatory requirements for early stage clinical trials with cell-based medicinal products. Christopher A Bravery
Regulatory requirements for early stage clinical trials with cell-based medicinal products Christopher A Bravery cbravery@advbiols.com Opening Remarks Cell-based medicinal products are in themselves diverse,
More informationCompetency 1: The student will demonstrate knowledge of the safety regulations that must be implemented at the biotechnology laboratory by:
Common Course Number: BSC-4420-L Course Title: Biotechnology Laboratory Catalog Course Description: This course provides students with practical, hands-on laboratory experiences to supplement the BSC-4330
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON SUMMARY OF REQUIREMENTS FOR ACTIVE SUBSTANCES IN PART II OF THE DOSSIER
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 28 January 1998 CPMP/QWP/297/97 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE
More informationACVM REGISTRATION STANDARD AND GUIDELINE FOR EFFICACY OF VACCINES
ISBN 0-478-07721-1 36 ACVM 07/04 New Zealand Food Safety Authority Post Office Box 2835 Wellington, New Zealand ACVM REGISTRATION STANDARD AND GUIDELINE FOR EFFICACY OF VACCINES This document may be altered
More informationGuideline on data requirements for immunological veterinary medicinal products intended for minor use or minor species (MUMS)/limited market
12 April 2017 EMA/CVMP/IWP/123243/2006-Rev.3 Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on data requirements for immunological veterinary medicinal products intended for minor
More informationIn ensuring the safety of veterinary vaccines demonstration of freedom from EA is one of high importance.
VICH/16/070 22 July 2016 Final Concept Paper for two VICH Guidelines: (1) general principles for detection of extraneous viruses in veterinary vaccines and defining the testing of seeds and materials of
More informationGUIDELINES FOR REGISTRATION OF VETERINARY BIOLOGICALS
DIRECTORATE: AGRICULTURAL INPUTS CONTROL GUIDELINES FOR REGISTRATION OF VETERINARY BIOLOGICALS This guideline has been prepared for applicants to indicate minimum requirements for registration of veterinary
More informationThe Road to Licensure of a DNA Vaccine for Atlantic Salmon
The Road to Licensure of a DNA Vaccine for Atlantic Salmon Nathalie C. Simard, Manager, Vaccines Research Novartis Animal Health Canada Inc. Aqua Health Business November 24th, 2008 Presentation Overview
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 London, 23 July 2009 EMEA/CHMP/BMWP/301636/2008 4 5 6 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE FINISHED DOSAGE FORM
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/126/95 FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE
More informationICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada
ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada Anthony Ridgway, Ph.D. Senior Regulatory Scientist Biologics & Genetic Therapies Directorate Health Canada Open
More informationThe Molecular Virology Support Core: Adenoviral Vectors and Beyond
The : Adenoviral Vectors and Beyond Christoph A. Kahl, Ph.D. Viral Vector Workshop, May 5th, 2011 Outline 1) Overview of the MVSC 2) Adenoviral Vectors 3) Expertise and Services Overview What does the
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationIBC protocol Risk Assessment and Determination of NIH Guidelines
IBC protocol Risk Assessment and Determination of NIH Guidelines The following are points to consider when reviewing all protocols for risk, recommended containment conditions, and determine applicable
More informationGenetic Engineering 1 of 27 Boardworks Ltd 2012
Genetic Engineering 1 of 27 Boardworks Ltd 2012 2 of 27 Boardworks Ltd 2012 What is genetic engineering? 3 of 27 Boardworks Ltd 2012 DNA of living organisms can be modified by the insertion or removal
More informationPRINCIPLES OF VETERINARY VACCINE PRODUCTION
NB: Version adopted by the World Assembly of Delegates of the OIE in May 2008 CHAPTER 1.1.6. PRINCIPLES OF VETERINARY VACCINE PRODUCTION SUMMARY A reliable supply of pure, safe, potent, and effective vaccines
More informationVirus- infectious particle consisting of nucleic acid packaged in a protein coat.
Chapter 19 Virus- infectious particle consisting of nucleic acid packaged in a protein coat. Most scientists consider viruses non-living because they cannot reproduce or carry out metabolic activities
More informationOutcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL
Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo
More informationLinker p. 177 Helper Lipid p. 178 Delivery to Target Cells p. 180 Cell Entry p. 182 Receptor-Mediated Uptake p. 182 Endosomai Release p.
Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials Introduction p. 1 Roles of Regulatory Scientists p. 2 Product Development and Availability p. 2 Data Requirements
More informationUNIVERSITY OF EXETER
UNIVERSITY OF EXETER Risk Assessment Of Genetically Modified Micro-organisms Where The Primary Risk Posed Is To Human Health Rather Than To The Environment This risk assessment form is for use in cases
More informationChapter 9. Biotechnology and DNA Technology
Chapter 9 Biotechnology and DNA Technology SLOs Compare and contrast biotechnology, recombinant DNA technology, and genetic engineering. Identify the roles of a clone and a vector in making recombined
More informationComparability Is Not a Nightmare, Just Think Ahead!
Comparability Is Not a Nightmare, Just Think Ahead! Margarida Menezes Ferreira Senior Assessor at INFARMED PT expert at BWP/CHMP - EMA member of the CAT - EMA (margarida.menezes@infarmed.pt) I attend this
More informationGuideline on setting specifications for related impurities in antibiotics
1 2 3 4 14 July 2010 EMA/CHMP/CVMP/QWP/199250/2009 Committee for Medicinal Products for Human Use (CHMP) / Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 7 Guideline on setting specifications
More informationCritical Steps for Approval of Adjuvanted Pandemic Vaccines
Critical Steps for Approval of Adjuvanted Pandemic Vaccines Gary Grohmann 8th Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 14 March 2008 Doc. Ref. EMEA/CVMP/182112/2006-CONSULTATION COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER
More informationRecommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines
Annex 4 Recommendations to assure the quality, safety and efficacy of recombinant hepatitis B vaccines Replacement of Annex 2 of WHO Technical Report Series, No. 786 and Annex 4 of WHO Technical Report
More informationRecombinant DNA Technology. The Role of Recombinant DNA Technology in Biotechnology. yeast. Biotechnology. Recombinant DNA technology.
PowerPoint Lecture Presentations prepared by Mindy Miller-Kittrell, North Carolina State University C H A P T E R 8 Recombinant DNA Technology The Role of Recombinant DNA Technology in Biotechnology Biotechnology?
More informationUnit 2: Metabolism and Survival Sub-Topic (2.7) Genetic Control of Metabolism (2.8) Ethical considerations in the use of microorganisms
Unit 2: Metabolism and Survival Sub-Topic (2.7) Genetic Control of Metabolism (2.8) Ethical considerations in the use of microorganisms Duncanrig Secondary JHM&MHC 2015 Page 1 of 18 On completion of this
More informationGuideline on Similar Biological Medicinal Products
1 2 3 22 May 2013 CHMP/437/04 Rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft 7 Draft agreed by Biosimilar Medicinal Products Working Party and Biologics Working Party March 2013
More informationVICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
More informationGuidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. Proposed guidelines
0 0 0 0 WHO/DRAFT/NCE_Adjuvanted vaccines/ April 0 ENGLISH ONLY Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines Proposed guidelines NOTE: This document has been prepared
More informationICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories.
European Medicines Agency November 2007 EMEA/CHMP/ICH/437986/2006 ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories Step 5
More informationPHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS
RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June
More information1225 Eye Street NW, Ste. 400 Washington, DC 20005
1225 Eye Street NW, Ste. 400 Washington, DC 20005 30 June 2005 EMEA Biologics Working Party Secretariat Attention: Linda Olsson European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4HB
More information7.1 Techniques for Producing and Analyzing DNA. SBI4U Ms. Ho-Lau
7.1 Techniques for Producing and Analyzing DNA SBI4U Ms. Ho-Lau What is Biotechnology? From Merriam-Webster: the manipulation of living organisms or their components to produce useful usually commercial
More informationOfficial Journal of the European Union DIRECTIVES
L 67/30 9.3.2018 DIRECTIVES COMMISSION DIRECTIVE (EU) 2018/350 of 8 March 2018 amending Directive 2001/18/EC of the European Parliament and of the Council as regards the environmental risk assessment of
More informationTANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF IMMUNOLOGICAL VETERINARY PRODUCTS.
DOC.TFDA/DMC/HVR/G/005 Revision No. 0 TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON SUBMISSION OF DOCUMENTATION FOR REGISTRATION OF IMMUNOLOGICAL VETERINARY PRODUCTS First Edition June 2017 P. O. Box
More informationGene Expression. Chapters 11 & 12: Gene Conrtrol and DNA Technology. Cloning. Honors Biology Fig
Chapters & : Conrtrol and Technology Honors Biology 0 Cloning Produced by asexual reproduction and so it is genetically identical to the parent st large cloned mammal: Dolly the sheep Animals that are
More informationDNA Cloning with Cloning Vectors
Cloning Vectors A M I R A A. T. A L - H O S A R Y L E C T U R E R O F I N F E C T I O U S D I S E A S E S F A C U L T Y O F V E T. M E D I C I N E A S S I U T U N I V E R S I T Y - E G Y P T DNA Cloning
More informationGenetics Lecture 21 Recombinant DNA
Genetics Lecture 21 Recombinant DNA Recombinant DNA In 1971, a paper published by Kathleen Danna and Daniel Nathans marked the beginning of the recombinant DNA era. The paper described the isolation of
More information